AU3693389A - Cloned gene for expression of antibodies reacting with human ovarian cancer - Google Patents

Cloned gene for expression of antibodies reacting with human ovarian cancer

Info

Publication number
AU3693389A
AU3693389A AU36933/89A AU3693389A AU3693389A AU 3693389 A AU3693389 A AU 3693389A AU 36933/89 A AU36933/89 A AU 36933/89A AU 3693389 A AU3693389 A AU 3693389A AU 3693389 A AU3693389 A AU 3693389A
Authority
AU
Australia
Prior art keywords
expression
ovarian cancer
human ovarian
cloned gene
antibodies reacting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU36933/89A
Inventor
David J.P. Fitzgerald
Ira H. Pastan
Mark C. Willingham
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Commerce
Original Assignee
US Department of Commerce
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Commerce filed Critical US Department of Commerce
Publication of AU3693389A publication Critical patent/AU3693389A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU36933/89A 1988-05-23 1989-05-19 Cloned gene for expression of antibodies reacting with human ovarian cancer Abandoned AU3693389A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19770388A 1988-05-23 1988-05-23
US197703 1988-05-23

Publications (1)

Publication Number Publication Date
AU3693389A true AU3693389A (en) 1989-12-12

Family

ID=22730416

Family Applications (1)

Application Number Title Priority Date Filing Date
AU36933/89A Abandoned AU3693389A (en) 1988-05-23 1989-05-19 Cloned gene for expression of antibodies reacting with human ovarian cancer

Country Status (3)

Country Link
AU (1) AU3693389A (en)
IL (1) IL90374A0 (en)
WO (1) WO1989011533A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5571894A (en) * 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
AU662311B2 (en) 1991-02-05 1995-08-31 Novartis Ag Recombinant antibodies specific for a growth factor receptor
US5939531A (en) * 1991-07-15 1999-08-17 Novartis Corp. Recombinant antibodies specific for a growth factor receptor

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0247091B1 (en) * 1985-11-01 1993-09-29 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use

Also Published As

Publication number Publication date
IL90374A0 (en) 1989-12-15
WO1989011533A1 (en) 1989-11-30

Similar Documents

Publication Publication Date Title
AU7247191A (en) Production of antibodies using gene libraries
AU4733989A (en) Gene family of tumor-associated antigens
AU633629B2 (en) Intermediates in the synthesis of oxa- and azahomoyclostatine polypeptides
AU568934B2 (en) New process for the synthesis of pyrido-imidazo-rifamycins
AU3006989A (en) Alteration of pharmacokinetics of proteins by charge modification
AU1565388A (en) Sensing of methane
AU625613B2 (en) Novel chimeric antibodies
AU2945189A (en) Synthesis of 1,2-dioxetanes and intermediates therefor
AU4354089A (en) A novel family of high affinity, modified antibodies for cancer treatment
AU4753090A (en) Production of ammonia from hydrocarbonaceous feedstock
AU3587489A (en) Monochromator drift compensation
AU1107188A (en) Monoclonal antibodies to glycopeptides of human cytomegalovirus
AU2946289A (en) Cloned dna for synthesizing unique glucocerebrosidase
AU7679687A (en) Monoclonal antibody specific for human colon fibroblast- derived t-pa
AU7784187A (en) Monoclonal antibody against ovarian cancer cells (ovb-3)
AU3693389A (en) Cloned gene for expression of antibodies reacting with human ovarian cancer
AU2075388A (en) Novel synthesis of 3-amino-2-methylbenzotrifluoride
AU2383288A (en) Human anti-rh(d) monoclonal antibodies
AU8966882A (en) Coal liquefaction process with controlled recycle of ethyl acetate-insolubles
GB8727030D0 (en) Production of monoclonal antibodies
AU6609686A (en) Detection of human cancer with a monoclonal antibody specific for antigen 9p650
AU572955B2 (en) Monoclonal antibody specific to gliadin protein of wheat
AU610736B2 (en) Process for the production of proteins
AU618720B2 (en) Monoclonal antibodies
EP0279669A3 (en) Monoclonal antibodies to human pancreatic cancer